Ultragenyx Pharmaceutical Inc RARE
News
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
Coinbase, Apple stocks falls while GitLab, Thor shares rally, and other stocks on the move
Ultragenyx, Mereo shares gain after positive results from study of bone disorder treatment
Ultragenyx Pharmaceutical Gets FDA Agreement to Expand GTX-102 Study